Radiotherapy dose-distribution to the perirectal fat space (PRS) is related to gastrointestinal control-related complications. by Gulliford, SL et al.
 Radiotherapy dose-distribution to the perirectal fat space (PRS) is related to 
gastrointestinal control-related complications 
 
SL Gulliford1 
S Ghose2 
MA Ebert 3,4 
A Kennedy3 
J Dowling5 
J Mitra2 
DJ Joseph3,6 
JW Denham7 
 
1 Joint Department of Physics, Institute of Cancer Research and Royal Marsden 
National Health Service Foundation Trust, Sutton, United Kingdom 
2 Department of Biomedical Engineering, Case Western Reserve University, 10900 
Euclid Ave, Cleveland, OH 44106 
3 Department of Radiation Oncology, Sir Charles Gairdner Hospital, Western Australia, 
Australia 
4 School of Physics, University of Western Australia, Western Australia, Australia 
5 Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia 
6 School of Surgery, University of Western Australia, Western Australia, Australia 
7 School of Medicine and Public Health, University of Newcastle, New South Wales, 
Australia 
 
 Correspondence address: 
Dr Sarah Gulliford 
Institute of Cancer Research 
15 Cotswold Road 
Belmont, Sutton, Surrey SM2 5NG 
United Kingdom 
Tel: +44 208 661 3320 
Email: sarahg@icr.ac.uk 
 
Running Title:  Dosimetric response of the Peri-Rectal Space 
 
 
Keywords:  Perirectal space, radiotherapy, atlas of complication, rectal toxicity 
  1 
Abstract 
Traditionally rectal symptoms following pelvic/prostate radiotherapy are correlated to 
the dosimetry of the anorectum or a substructure of this.  It has been suggested that the 
perirectal fat space (PRS) surrounding the rectum may also be relevant.  This study 
considers the delineation and dosimetry of the PRS related to both rectal bleeding and 5 
control-related toxicity.  Initially, a case-control cohort of 100 patients from the 
RADAR study were chosen based on presence/absence of rectal control-related toxicity. 
Automated contouring was developed to delineate the PRS.    79 of the 100 auto-
segmentations were considered successful.  Balanced case-control cohorts were defined 
from these cases.   Atlas of Complication Incidence (ACI) were generated to relate the 10 
DVH of the PRS with specific rectal symptoms; rectal bleeding and control-related 
symptoms (LENT/SOM).    ACI demonstrated that control-related symptoms were 
related to the dose distribution to the PRS which was confirmed with Wilcoxon  rank 
sum test (p<0.05).   To the authors knowledge this is the first study implicating the dose 
distribution to the PRS to the incidence of control-related symptoms of rectal toxicity. 15 
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INTRODUCTION 
The range of rectal/bowel symptoms reported following prostate radiotherapy is diverse 
including rectal bleeding and control-related symptoms such as loose stools and 20 
urgency. The dosimetric relationship to the specific toxicity of rectal bleeding has been 
comprehensively studied and characterised [1].  For other endpoints the aetiology and 
relationship with dosimetry is less well defined and the subject of ongoing 
investigations [2-4].  However several studies reporting the rectal toxicity from large 
prospective clinical trials found differences in the anatomical subregions and dosimetric 25 
variables which related to individual toxicity outcomes[5-9].   A study by Smeenk et al 
which considered the dosimetric relationship between the anal wall and pelvic floor 
muscle groups and incontinence-related toxicity demonstrated specific dose-response 
relationships with individual muscle groups [10].  Buettner at al [11] demonstrated that 
spatial descriptors of the dose received by the surface of anal canal (defined as the 30 
caudal 3cm of the anorectum) were correlated to sphincter control (LENT SOM)[12].  It 
is apparent that different manifestations of toxicity are related to different underlying 
pathophysiology, including inflammatory responses and epithelial damage  [9, 10]. 
 
It is well recognised that rectal dose volume histograms (DVHs) obtained during 35 
prostatic irradiation  differ  from those derived during the radiotherapy planning process 
[13]. However, the surrounding region, the perirectal fat space (PRS), is thought to 
remain relatively immobile. If this is true, then it may also be true that the DVH of the 
PRS derived during planning will correlate more satisfactorily with subsequent 
radiation induced dysfunctional rectal symptoms than the rectal DVH generated during 40 
planning. 
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Moreover, if peri-rectal fat is as radiosensitive as other fatty tissue regions in the body, 
it is possible that a course of prostatic irradiation will reduce the elasticity of peri-rectal 
fat, which may in its own right alter rectal function adversely. Therefore, in this study 45 
we test the hypothesis that DVHs of the PRS obtained at planning correlates better with 
the severity of dysfunctional rectal symptoms and their underlying injuries than 
planning rectal DVHs. 
 
METHODS AND MATERIALS 50 
Data source and description 
The RADAR trial (Randomised Androgen Deprivation and Radiotherapy, TROG 03.04) 
[14] examined the influence of duration of androgen deprivation (AD) with or without 
bisphosphonates, adjuvant with radiation therapy, for treatment of prostate carcinoma. 
1071 participants were accrued from 23 centres across Australia and New Zealand 55 
between 2003 and 2007. 
 
All participants received centre-nominated radiation therapy to the prostate with 46 Gy 
3D conformal external beam radiation therapy (EBRT – “Phase 1”) followed by either a 
19.5-Gy high dose-rate (HDR) brachytherapy boost or EBRT to either 66, 70, 74, or 78 60 
Gy (at clinician discretion - “Phase 2”). Phase 1 was determined by PTV1, being CTV 
plus 10 mm margin in all directions except posteriorly where it was 5 mm. Phase 2 was 
determined by PTV2, being CTV plus 0 - 10 mm margin in all directions except 
posteriorly where it was 0 – 5 mm. Fractionation is shown in Table 1. No participants 
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receiving the HDR boost were considered in this current study. Image guidance was via 65 
bony anatomy only. 
 
Rectal dose volume constraints, derived from results presented by Boersma et al [15], 
were applied during treatment planning.  They were 65, 70, and 75 Gy to a maximum 
40%, 30%, and 5% of rectum , respectively. 70 
 
All patients were assessed at randomization (baseline) and then routinely followed in 
clinic every 3 months for 18 months, then at 6 months up to 5 years post randomization 
and then annually. At these visits, toxicity was assessed according to Late Effects of 
Normal Tissues Subjective, Objective, Management, and Analytic (LENT SOMA) 75 
scales [12]. 
 
Participant treatment planning data (CT images, planned dose distributions, delineate 
anatomy, beam configurations and treatment demographic data) were archived in a 
database using the SWAN software system [16], enabling subsequent query and 80 
arbitrary analysis. 
 
Definition of the PRS region 
The PRS is here defined as the region of tissue, mostly fat, which the rectum can 
expand into or contract from [17]. Although the spatial extent of the fat region is 85 
relatively apparent on CT images, the extent of the fat which, when irradiated, could 
lead to rectal toxicity is ambiguous. As such, for this investigation, the entire region of 
fat adjacent to the prostate, rectum and bladder, though excluding any of the interior of 
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those structures, was initially incorporated into defining the PRS. In order to optimise 
potentially causal dosimetric correlations, a sub-section of this region was then 90 
examined for statistical analysis as described below. 
Segmentation of PRS 
Due to the complexity and convoluted nature of the PRS region, manual segmentation 
on a large number of cases was considered infeasible. An auto-segmentation method 
was established based on manual delineation by a single observer (JD) on a series of ten 95 
test cases. A thorough description of the auto-segmentation process has been presented 
elsewhere [18].  
  
In summary, on each analysed CT image set, the auto-segmentation involved defining a 
probability map for the PRS region based on non-rigid registration to the test cases.  100 
The voxels within the volume of interest were then labelled using an expectation 
maximisation clustering.  The resulting structure was represented as a binary mask on 
each patient’s CT images. For the purpose of correlating PRS dosimetric factors with 
toxicity, the structure was refined by only including defined PRS image-pixels within 
50 mm of the previously-delineated anorectum structure [8], as well as caudal to the 105 
bladder neck, and excluding any pixels within the outer wall of the rectum, as delineated 
at patient treatment planning. This ensured that the fat region immediately adjacent to 
the rectum was included in the dosimetric analysis excluding the fat region posterior to 
the bladder. It was also desired that the superior-inferior extent of the region should 
encompass the borders of the coplanar beams oriented about the cranio-caudal axis. 110 
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The auto-segmentation process was computationally intensive and, as such, a subset of 
100 of the available RADAR patients (treated entirely with EBRT) was selected for 
auto-segmentation.  This was a case-control analysis representing patients with control-
related toxicity (requiring LENT SOMA ‘stool frequency’ ≥ grade 2 and ‘urgency and 115 
tenesmus’ ≥ grade 2 at any time throughout a minimum 60 months follow-up) and 
without control-related toxicity (grade = 0  throughout a minimum 60 months follow-
up).  The anorectum and anal canal were also outlined separately for comparison.  The 
anorectum was delineated as the outer rectal wall from the ischial tuberosities until the 
level where the rectum turns horizontally into the sigmoid colon, of which the anal 120 
canal was considered to be the caudal 3cm [5]. 
 
Once segmented, cohorts with balanced characteristics were defined based on 
prescription dose, rectal and PRS volume and age at treatment. 
 125 
Derivation of DVHs 
Dose distributions from each treatment phase were combined on a voxel-by-voxel basis. 
DVH for the anorectum, anal canal and  refined PRS regions were independently 
calculated as defined in Kennedy et al [19]. Since the PRS is an undescribed structure in 
terms of radiobiology, physical dose was used for the study. The DVH data were 130 
imported, with toxicity data, to Matlab version 2013a (Mathworks, Natick, MA).  The 
relationship between dosimetry and toxicity was explored using Atlas of Complication 
Incidence (ACI) [20, 21]  which were generated using a grid of 5 Gy dose and 10% 
volume bins. The denominator in each grid square indicates the number of patients 
whose DVH passed through whilst the numerator indicates the number of those patients 135 
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who reported complications.  ACI were generated to present the incidence of control-
related toxicity for each of the outlined structures.  For completeness ACI were also 
generated for rectal bleeding >= G2.   
Statistical Considerations 
A spearman’s correlation matrix was generated to assess correlations between 140 
dosimetric descriptors of the 3 structures considered in this study PRS, anorectum and 
anal canal. Non parametric comparisons between the dosimetry of patients who did/did 
not report toxicity were made using Wilcoxon  rank sum test.  A Holm-Bonferroni 
correction was made to account for multiple testing of different dose levels. All 
statistical analysis was undertaken using R.[22]   145 
RESULTS 
Of the 100 patients chosen for auto-segmentation, 79 datasets were considered 
sufficiently well delineated for inclusion in the analysis. Figure 1 present examples of 
the automatically defined PRS regions. 34 patients who did not report rectal control 
related toxicity had successful PRS delineation and these were balanced against 34 150 
patients who reported rectal control-like toxicity.  Table 1 details the patient 
characteristics of the 68 patients included in the dosimetric analysis.  There were no 
significant differences between the groups with and without control-related toxicity in 
terms of prescription, rectal and PRS volume, BMI or age at treatment. The correlation 
matrix (Appendix Figure A5) indicates a high degree of correlation between the 155 
dosimetric variables of a particular structure but low correlation between structures. 
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The ACI relating the dose distribution to the PRS with rectal control-related toxicity is 
presented in Figure 2. Figure 3 shows the ACI for the subgroup of patients who reported 
control-related toxicity but who did not report rectal bleeding. The ACI relating the 160 
dose distribution to the PRS with rectal bleeding (≥G2) is shown in Figure 4. Wilcoxon  
rank sum test results are presented in Table 2 where a number of dose levels were 
shown to be related to control-related toxicity for the PRS, when including all patients 
and also when excluding patients with rectal bleeding.  However no results remained  
statistically significant after applying the Holm-Bonferroni correction.  There were no 165 
statistically significant results when relating the PRS to Grade 2 Rectal Bleeding.  
 
 
The ACI for the anorectum (Appendix Figures A1 and A2) do not demonstrate a clear 
dosimetric relationship with either rectal bleeding or control-related toxicity.  However, 170 
the ACI for the anal canal (Appendix Figures A3 and A4) indicate a dose-response for 
both toxicity endpoints.  These results were confirmed by  statistical analysis,   but did 
not remain significant when the Holm-Bonferroni correction was applied. 
DISCUSSION 
Technological improvements enable radiotherapy delivery to be optimised to individual 175 
anatomy and function. This provides an opportunity to capitalise on an improved 
understanding of dose-response for discrete treatment complications. This study has 
focused on elucidating a more complete aetiology for a subset of gastrointestinal 
complications, utilising recent developments in non-linear image registration and 
autosegmentation. 180 
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The ACI and statistical analysis indicate that the strongest relationship between the 
outlined structures and control-related toxicity is described by the dose distribution to 
the PRS.  Although the definition of the region is still ambiguous, it is hoped that 
development of voxel-level investigations as a means of refining the definition will 185 
develop a consensus of the structure delineation. Associated analysis, including 
assessment of inter-observer agreement, is underway. 
 
The ACI relating anorectal DVH with rectal bleeding did not demonstrate a clear dose 
response.  This study presents results on a small cohort reflecting the development 190 
efforts in auto-segmentation of the PRS and case selection to specifically explore the 
relationship with control related toxicity.  It has been shown that the dose distribution of 
the PRS is not highly correlated with that of the anorectum and anal canal,  However, 
the results from a previous study utilising all available data from the RADAR study [8] 
do demonstrate a relationship between mid-high doses and rectal bleeding and between 195 
lower doses to the anal canal and urgency.   Previous publications [11, 23] have also 
indicated that the dose distribution to the anal canal is related to control-related 
symptoms.  These results appear to be corroborated by the anal canal atlas presented in 
this study.   
 200 
The ACI relating PRS DVH to control-like toxicities (Figure 2) shows a clear pattern of 
increasing incidence rates with increasing dose and volume. This is apparent even when 
isolated just to patients without incidence of rectal bleeding (Figure 3). The statistical 
results presented in Table 2 strongly support the hypothesis that the PRS behaves as a 
parallel-responding structure with significant dose-volume parameters across a broad 205 
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range of doses, and a significant dependence on the mean but not maximum dose. It 
must be highlighted that  duration of AD  was significantly different between the patient 
groups (see Table 1). Although an attempt was made to match the groups based on their 
toxicity incidence using prescription dose, rectal volume and age at treatment, there 
were not sufficient patient numbers to allow control of all other factors. Previous 210 
analyses of the entire RADAR cohort have not uncovered significant impacts of AD 
duration or age [24, 25]. Similarly note that no rectal filling procotol was specified for 
the trial and uniform proportions of any applied protocols between the toxicity groups 
cannot be guaranteed. 
 215 
Given the role of the PRS in facilitating rectal motility, compliance and control, and the 
potential for fatty atrophy and fibrosis on irradiation, there is reason to hypothesise a 
causal relationship between dose to the PRS and subsequent control-related 
gastrointestinal symptoms. Moreover, a large number of sympathetic, parasympathetic 
and non-autonomic nerve fibres are to be found in the perirectal fat space. Radiation 220 
injury to the vasa nervorum may therefore directly lead to nerve dysfunction and 
contribute to control-related symptoms (personal communication 2017 Drs Jervoise 
Andreyev and Andrew Wotherspoon). 
 
To our knowledge, this is the first study of the dosimetric relationship between the PRS 225 
and control-related gastrointestinal toxicity.  The dataset utilised was selected on the 
basis of availability, number of available participants, completeness and extent of 
follow-up. It must be acknowledged that the use of relatively dated treatment 
techniques, without image-guidance other than for bony anatomy, will likely influence 
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applicability to contemporary treatments. The use of soft-tissue image-guidance and 230 
more conformal delivery techniques are known to impact on delivered dose 
distributions and toxicity incidence [26, 27]. Validation in relevant datasets is desirable, 
including assessment of the mobility of the PRS on inter-fraction images. Further study 
of the individual structures within the PRS may provide more specific information 
relating dosimetry to toxicity. 235 
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Figure Captions 
Figure 1: Examples of autosegmented and and processed PRS regions shown as a light-250 
grey mask on axial, coronal and sagittal reconstructions. 
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Figure 2: Atlas of complication incidence (ACI) relating the perirectal space (PRS) with 
control-like rectal toxicity described using LENT/SOMA.  The denominator in each box 
indicates the number of patients whose dvh passes through whilst the numerator details 255 
how many of those patients reported control-like rectal toxicity.  Hot (red) regions of 
the colour scale indicate high incidence and cold (blue) regions indicate low incidence.  
The bottom right hand box indicates overall incidence in the cohort (shaded green). 
 
Figure 3: Atlas of complication incidence (ACI) relating the perirectal space (PRS) with 260 
control-like rectal toxicity described using LENT/SOMA.  Patients who reported rectal 
bleeding were excluded. 
 
Figure 4: Atlas of complication incidence (ACI) relating the perirectal space (PRS) with 
Grade 2 rectal bleeding (LENT/SOMA). 265 
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 Whole Group No Control-related 
Rectal -Toxicity 
Control-related 
Rectal Toxicity 
N 68 34 34 
Trial arma, n (%) 
A 
B 
C 
D 
 
17 (25%) 
17 (25%) 
16 (24%) 
18 (26%) 
 
9 (26%) 
11 (32%) 
6 (18%) 
8 (24%) 
 
8 (24%) 
6 (18%) 
10 (29%) 
10 (29%) 
Prescription dose 
group, n (%) 
66 Gyb 
70 Gyc 
74 Gyc 
 
 
10 (15%) 
35 (51%) 
23 (34%) 
 
 
6 (18%) 
13 (38%) 
15 (44%) 
 
 
4 (9%) 
22 (65%) 
8 (22%) 
Rectal volume, 
mean (SD) 
77.1 (40.7) cm3 84.5* (48.0) cm3 69.7 (30.8) cm3 
Risk group 
Intermediate 
High 
 
47 (69%) 
21 (31%) 
 
20 (59%) 
14 (41%) 
 
27 (71%) 
7 (21%) 
BMI, mean (SD) 27.6 (3.4) 27.9 (3.4) 27.4 (3.5) 
PRS volume, mean 
(SD) 
140.7 (51.4) cm3 149.3 (49.0) cm3 132.2 (53.1) cm3 
Age at treatment, 
mean (SD) 
70.6 (6.1) 71.4 (5.5) 69.7 (6.6) 
≥ G2 peak rectal 
bleeding, n (%) 
23 (34%) 5 (15%) 18 (55.9%) 
Table 1.  Patient Characteristics 
 
a A – 6 months androgen suppression; B – 6 months androgen suppression + 
zoledronic acid; C – 18 months androgen suppression; D – 18 months androgen 
suppression + zoledronic acid 
b 33 fractions, 2 Gy/fraction, PTV1 within 95% isodose 
c Phase 1 - 30 fractions, 2 Gy/fraction, PTV1 within 95% isodose. Phase 2 - 
additional dose in 2 Gy/fraction, PTV2 within 95% isodose 
 
 
  Perirectal Space DVH Ano-Rectum DVH Anal Canal DVH 
Dose 
Metric 
Other 
Toxicity 
Other Toxicity 
(RB < G2) 
Rectal 
Bleeding G2 
Other 
Toxicity 
Other Toxicity 
(RB < G2) 
Rectal 
Bleeding G2 
Other 
Toxicity 
Other Toxicity 
(RB < G2) 
Rectal 
Bleeding G2 
  n=68 n=44 n=68 n=68 n=44 n=68 n=68 n=44 n=68 
V5 0.163 0.620 0.088 0.154 0.421 0.454 0.123 0.168 0.328 
V10 0.031 0.293 0.184 0.421 0.413 0.974 0.085 0.110 0.280 
V15 0.025 0.168 0.571 0.611 0.620 0.568 0.173 0.143 0.433 
V20 0.029 0.070 0.964 0.677 0.544 0.107 0.195 0.276 0.332 
V25 0.034 0.063 0.894 0.579 0.314 0.050 0.071 0.235 0.411 
V30 0.014 0.030 0.854 0.332 0.103 0.073 0.048 0.200 0.302 
V35 0.037 0.013 0.448 0.296 0.114 0.157 0.066 0.302 0.326 
V40 0.015 0.005 0.362 0.083 0.047 0.264 0.057 0.338 0.130 
V45 0.072 0.146 0.904 0.424 0.677 0.864 0.185 0.922 0.028 
V50 0.107 0.192 0.954 0.308 0.732 0.964 0.164 0.748 0.013 
V55 0.089 0.175 0.954 0.258 0.788 0.814 0.164 0.902 0.013 
V60 0.089 0.209 0.814 0.206 0.864 0.411 0.112 0.795 0.005 
V65 0.189 0.291 0.774 0.118 0.677 0.181 0.085 0.406 0.011 
V70 0.931 0.535 0.748 0.602 0.553 0.255 0.740 0.806 0.316 
mean 0.025 0.067 0.995 0.134 0.248 0.794 0.065 0.418 0.071 
max 0.289 0.872 0.653 0.374 0.569 0.379 0.492 0.473 0.087 
Table 2 Wilcoxon rank sum test p values, relating individual dose metrics for the PRS, anorectum and anal canal to rectal control-like symptoms and 
bleeding.  Results with an (uncorrected) p value <0.05 shown in bold. 
 Figure 1: Examples of autosegmented and processed PRS regions shown as a light-grey mask on 
axial, coronal and sagittal reconstructions. 
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Figure 2: Atlas of complication incidence (ACI) relating the perirectal space (PRS) with control-like 
rectal toxicity described using LENT/SOMA.  The denominator in each box indicates the number of 
patients whose dvh passes through whilst the numerator details how many of those patients 
reported control-like rectal toxicity.  Hot (red) regions of the colour scale indicate high incidence and 
cold (blue) regions indicate low incidence.  The bottom right hand box indicates overall incidence in 
the cohort (shaded green). 
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Figure 3: Atlas of complication incidence (ACI) relating the perirectal space (PRS) with control-like 
rectal toxicity described using LENT/SOMA.  Patients who reported rectal bleeding were excluded. 
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 Figure 4: Atlas of complication incidence (ACI) relating the perirectal space (PRS) with Grade 2 rectal 
bleeding (LENT/SOMA). 
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 Figure A1: Atlas of complication incidence (ACI) relating the anorectum with control-like rectal 
toxicity described using LENT/SOMA.  The denominator in each box indicates the number of patients 
whose dvh passes through whilst the numerator details how many of those patients reported 
control-like rectal toxicity.  Hot (red) regions of the colour scale indicate high incidence and cold 
(blue) regions indicate low incidence.  The bottom right hand box indicates overall incidence in the 
cohort (shaded green). 
 
Figure A2: Atlas of complication incidence (ACI) relating the anorectum with Grade 2 rectal bleeding 
described using LENT/SOMA. 
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 Figure A3: Atlas of complication incidence (ACI) relating the anal canal with control-like rectal 
toxicity described using LENT/SOMA. 
 
Figure A4: Atlas of complication incidence (ACI) relating the anal canal with Grade 2 rectal bleeding 
described using LENT/SOMA. 
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 Figure A5: Correlation matrix for dosimetric parameters of the PeriRectal Space (PRS), 
Anorectum(AR) and Anal Canal (AC). 
 
